{"id":172833,"date":"2025-12-01T07:50:13","date_gmt":"2025-12-01T12:50:13","guid":{"rendered":"https:\/\/old.alphastreet.com\/india\/?p=172833"},"modified":"2025-12-01T07:50:13","modified_gmt":"2025-12-01T12:50:13","slug":"emcure-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/emcure-q2-fy26-earnings-results\/","title":{"rendered":"Emcure Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Emcure Pharmaceuticals Ltd , incorporated in 1981 and a global manufacturer and marketer of pharmaceutical products, reported strong financial results for Q2FY26.<\/p>\n<h2>Financial Highlights:<\/h2>\n<ul>\n<li>Revenues increased 13.39% year-on-year to \u20b92,270 crore from \u20b92,002 crore.<\/li>\n<li>Total expenses rose 9.52% to \u20b91,932 crore from \u20b91,764 crore.<\/li>\n<li>Consolidated net <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/5d0d8415-d775-41fe-aae8-92053a1ecac1.pdf\" target=\"_blank\" rel=\"noopener\">profit<\/a> grew 24.26% to \u20b9251 crore from \u20b9202 crore.<\/li>\n<li>Earnings per share improved 24.78% to \u20b912.84 from \u20b910.29.<\/li>\n<\/ul>\n<p>Growth was driven by strong domestic and international sales, operational efficiency, a broad therapeutic portfolio, and strategic partnerships.<\/p>\n<h2>Outlook:<\/h2>\n<p>Emcure Pharmaceuticals Ltd focuses on expanding global footprint, innovative product launches, and enhancing manufacturing capabilities to sustain growth momentum.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/alphastreet.com\/india\/symbol\/emcure\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-172844\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Emcure Pharmaceuticals Ltd , incorporated in 1981 and a global manufacturer and marketer of pharmaceutical products, reported strong financial results for Q2FY26. Financial Highlights: Revenues increased 13.39% year-on-year to \u20b92,270 crore from \u20b92,002 crore. Total expenses rose 9.52% to \u20b91,932 crore from \u20b91,764 crore. Consolidated net profit grew 24.26% to \u20b9251 crore from \u20b9202 crore. [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":172844,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-172833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":171315,"url":"https:\/\/alphastreet.com\/india\/emcure-q1-fy26-earnings-results-2\/","url_meta":{"origin":172833,"position":0},"title":"Emcure Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 17, 2025","format":false,"excerpt":"Company Overview: Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally, serving diverse therapeutic segments. Presenting below its Q1 FY26 Earnings Results. Financial Highlights for Q1 FY26: Revenue: \u20b92,101 crore, up 15.76% year-on-year from \u20b91,815 crore Total Expenses: \u20b91,810 crore, up 10.91% year-on-year from \u20b91,632 crore Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"EMCURE Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169071,"url":"https:\/\/alphastreet.com\/india\/emcure-pharmaceuticals-ltd-q4fy25-63-rise-in-profits\/","url_meta":{"origin":172833,"position":1},"title":"Emcure Pharmaceuticals Ltd Q4FY25; 63% rise in Profits","author":"Divyansh_Kasana","date":"July 9, 2025","format":false,"excerpt":"Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally Financial Results: Emcure Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,116.00 Crores up from \u20b91,771.00 Crore year on year, a rise of 19.48%. Total Expenses for Q4FY25 of \u20b91,850.00 Crores up from \u20b91,616.00 Crores year on year, a\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179601,"url":"https:\/\/alphastreet.com\/india\/emcure-pharmaceuticals-q3-fy26-earnings-results\/","url_meta":{"origin":172833,"position":2},"title":"Emcure Pharmaceuticals Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"February 5, 2026","format":false,"excerpt":"Executive Summary Emcure Pharmaceuticals Ltd reported Q3FY26 revenues of \u20b92,363 crore, up 20.38% YoY, with consolidated net profit surging 48.08% to \u20b9231 crore despite \u20b938 crore one-time labour code expenses. International sales exceeded 50% revenue mix with 24.5% growth, complemented by strong domestic chronic therapy performance. Revenue & Growth Revenues\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171282,"url":"https:\/\/alphastreet.com\/india\/emcure-q1-fy26-earnings-results\/","url_meta":{"origin":172833,"position":3},"title":"EMS Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 17, 2025","format":false,"excerpt":"Company Overview: EMS Limited is a multi-disciplinary EPC company based in Delhi, specializing in turnkey services for water and wastewater collection, treatment, and disposal. It offers end-to-end services from engineering and design to construction and installation of water, wastewater, and domestic waste treatment facilities. Presenting below its Q1 FY26 Earnings\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"EMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMS-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMS-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMS-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMS-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMS-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMS-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":124783,"url":"https:\/\/alphastreet.com\/india\/ipo-alert-what-to-expect-when-emcure-pharma-hits-public-markets\/","url_meta":{"origin":172833,"position":4},"title":"IPO Alert: What to expect when Emcure Pharma hits public markets","author":"Nishadkishore","date":"September 3, 2021","format":false,"excerpt":"India's domestic pharmaceutical market is estimated at $42 billion in 2021. It is likely to reach $65 billion by 2024 and further expand to $120-130 billion by 2030. Meanwhile, the Indian domestic formulations market grew at a healthy combined annual rate of 7% from 2018 to 2021. The domestic formulations\u2026","rel":"","context":"In &quot;Health Care&quot;","block_context":{"text":"Health Care","link":"https:\/\/alphastreet.com\/india\/category\/healthcare-stocks\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/07\/iStock-649278704.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/07\/iStock-649278704.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/07\/iStock-649278704.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/07\/iStock-649278704.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/07\/iStock-649278704.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":172881,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-q2-fy26-earnings-results\/","url_meta":{"origin":172833,"position":5},"title":"Akums Drugs Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 3, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004 as India's leading pharmaceutical CDMO offering comprehensive product development and manufacturing services across formulations, reported lower profitability for Q2FY26. Financial Highlights: Revenues declined 1.45% year-on-year to \u20b91,018 crore from \u20b91,033 crore, with CDMO up 0.7% to \u20b9804 crore but API\/international formulations down.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172833"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172833\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}